Highlights Amgen Inc.

Equities

AMGN

US0311621009

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2026-01-23 pm EST			5-day change	1st Jan Change
344.75 ^USD	-0.67%		+4.46%	+5.33%

09:00am	The Market's Favorite Question Right Now: Is This a Return to Normal, or Just a Pause?
05:47am	Bernstein Downgrades Amgen to Market Perform From Outperform, Price Target is $335	MT

Highlights

09:00am	The Market's Favorite Question Right Now: Is This a Return to Normal, or Just a Pause?
Jan. 14	Honeywell Says Quantinuum Plans Confidential Filing of IPO Draft Registration	MT
Jan. 13	Ro partners with Amgen to study barriers to obesity care, GLP-1 access	RE
Jan. 13	Ro announces research collaboration with Amgen to evaluate real-world GLP-1 coverage	RE
Jan. 13	Focus on inflation and corporate earnings
Jan. 12	Amgen says MariTide helped trial patients maintain weight loss	RE
Jan. 08	Evotec Remains in Demand on Tradegate – Funding Secured for Subsidiary	DP
Jan. 07	Evotec Continues Upward Trend Following Amgen's Acquisition of Dark Blue	DP
Jan. 07	DISCO Pharmaceuticals Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies	CI
Jan. 06	PRESS DIGEST- Financial Times - January 7	RE
Jan. 06	Amgen acquires Dark Blue Therapeutics, bolstering oncology pipeline	RE
Jan. 06	Amgen Buys Dark Blue Therapeutics in Deal Worth Up to $840 Million	DJ
Jan. 06	Dark Blue Therapeutics acquired by Amgen for up to $840 million	RE
Jan. 06	Amgen Acquires Dark Blue Therapeutics for $840 Million	MT
Jan. 06	Amgen acquires Dark Blue Therapeutics for up to $840 million	RE
Jan. 05	Zenas shares plunge on weaker-than-expected data for immune disorder drug	RE
Jan. 05	Zenas BioPharma's immune disorder drug meets main goal in late-stage trial	RE
Jan. 04	Amgen Inc. acquired Dark Blue Therapeutics Ltd from Oxford Science Enterprises, Bristol-Myers Squibb Company and Evotec SE in a transaction valued at $840 million.	CI
Dec. 29	Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer	CI
Dec. 19	US FDA grants priority vouchers to Merck's cholesterol pill, cancer therapy	RE
Dec. 19	Sector Update: Health Care Stocks Rise Late Afternoon	MT
Dec. 19	Trump Reportedly Strikes Drug Price Deals With Nine Pharma Companies	MT
Dec. 18	Takeda's AI-crafted psoriasis pill succeeds in late-stage studies	RE
Dec. 16	GSK wins US approval for twice-yearly asthma drug	RE
Dec. 12	FDA Approves Amgen's Uplizna (inebilizumab-cdon) for Generalized Myasthenia Gravis	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Highlights Amgen Inc.

Equities

AMGN

US0311621009

Pharmaceuticals

Highlights

Filters